Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biopharmaceutical” or “the Company”), founded in 1988, is a state-level high-tech enterprise specializing in the research, production, and marketing of vaccines and diagnostic reagents for infectious diseases. The Company has always adhered to the mission of “being a responsible player in the biopharmaceutical industry for human health!” and has actively participated in the research of major national science and technology projects and the development of five industry standards. Over the past 39 years, through independent innovation and research, the Company has continuously optimized and enhanced its scientific research capabilities and industrial production capacity. Based on advanced production processes and stricter product registration standards compared to pharmacopoeias, the Company has developed a diverse range of research pipelines and innovative, upgraded products. Several of its product developments and clinical progress have reached the top tier in China. The Company will further leverage its comprehensive competitive advantages in product development innovation, large-scale production, sales channels, and quality management to drive the high-quality development of its technological innovation and industrial capacity, serve the national strategy of health and public health security, and benefit the people.
